NBIX

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 10

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,802

Underlying: Common Stock · 1,401 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award.

F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award.

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 8

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,225

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 7

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,980

F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 6

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,045

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 5

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 4

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,420

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · derivative · entry 8

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,377

Underlying: Common Stock · 5,377 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, vested as to 5,377 shares on February 13, 2026, and will vest as to 5,377 shares on February 13, 2027, subject to the terms and conditions of the award.

F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, vested as to 5,377 shares on February 13, 2026, and will vest as to 5,377 shares on February 13, 2027, subject to the terms and conditions of the award.

SEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · derivative · entry 7

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,208

Underlying: Common Stock · 5,604 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, vested as to 5,604 shares on February 13, 2026, and will vest as to 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award.

F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, vested as to 5,604 shares on February 13, 2026, and will vest as to 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award.

SEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 6

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 551,293

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

F3 · balance_after: 551,293 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

SEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 5

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 585,673

F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.

SEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 4

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 521,949

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 3

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 524,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 519,473

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 522,497

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818524-26-000002 · wk-form4_1771368237.xml · derivative · entry 2

Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,285

Underlying: Common Stock · 6,285 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

SEC source: 0001818524-26-000002 · wk-form4_1771368237.xml · derivative · entry 1

Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,827

Underlying: Common Stock · 35,827 shares

Expires 2036-02-13

F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

SEC source: 0001724097-26-000005 · wk-form4_1771368557.xml · derivative · entry 9

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,401

Underlying: Common Stock · 2,133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,133 shares on February 12, 2026, and will vest as to 2,133 shares on February 12, 2027, 2,134 shares on February 12, 2028, and 2,134 shares on February 12, 2029, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,133 shares on February 12, 2026, and will vest as to 2,133 shares on February 12, 2027, 2,134 shares on February 12, 2028, and 2,134 shares on February 12, 2029, subject to the terms and conditions of the award.

SEC source: 0001724097-26-000005 · wk-form4_1771368557.xml · nonDerivative · entry 2

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,079

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001724097-26-000005 · wk-form4_1771368557.xml · nonDerivative · entry 1

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,230

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · derivative · entry 9

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,801

Underlying: Common Stock · 1,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock .

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award.

SEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 2

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,449

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,313

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · derivative · entry 9

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,721

Underlying: Common Stock · 4,907 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 4,907 shares on February 12, 2026, and will vest as to 4,907 shares on February 12, 2027, 4,907 shares on February 12, 2028, and 4,907 shares on February 12, 2029, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 4,907 shares on February 12, 2026, and will vest as to 4,907 shares on February 12, 2027, 4,907 shares on February 12, 2028, and 4,907 shares on February 12, 2029, subject to the terms and conditions of the award.

SEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 2

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,013

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 1

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,661

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 9

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,681

Underlying: Common Stock · 2,560 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,560 shares on February 12, 2026, and will vest as to 2,560 shares on February 12, 2027, 2,560 shares on February 12, 2028, and 2,560 shares on February 12, 2029, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,560 shares on February 12, 2026, and will vest as to 2,560 shares on February 12, 2027, 2,560 shares on February 12, 2028, and 2,560 shares on February 12, 2029, subject to the terms and conditions of the award.

SEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 2

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,111

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 1

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,537

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · derivative · entry 9

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,161

Underlying: Common Stock · 1,387 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,387 shares on February 12, 2026, and will vest as to 1,387 shares on February 12, 2027, 1,387 shares on February 12, 2028, and 1,387 shares on February 12, 2029, subject to the terms and conditions of the award.

F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,387 shares on February 12, 2026, and will vest as to 1,387 shares on February 12, 2027, 1,387 shares on February 12, 2028, and 1,387 shares on February 12, 2029, subject to the terms and conditions of the award.

SEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,240

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 9

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,017

Underlying: Common Stock · 2,005 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,005 shares on February 12, 2026, and will vest as to 2,005 shares on February 12, 2027, 2,005 shares on February 12, 2028, and 2,005 shares on February 12, 2029, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,005 shares on February 12, 2026, and will vest as to 2,005 shares on February 12, 2027, 2,005 shares on February 12, 2028, and 2,005 shares on February 12, 2029, subject to the terms and conditions of the award.

SEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 2

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,678

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 1

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 10

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,377

Underlying: Common Stock · 1,792 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,792 shares on February 12, 2026, and will vest as to 1,792 shares on February 12, 2027, 1,792 shares on February 12, 2028, and 1,792 shares on February 12, 2029, subject to the terms and conditions of the award.

F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,792 shares on February 12, 2026, and will vest as to 1,792 shares on February 12, 2027, 1,792 shares on February 12, 2028, and 1,792 shares on February 12, 2029, subject to the terms and conditions of the award.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,617

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,584

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 9

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,801

Underlying: Common Stock · 1,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award.

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,775

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,656

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001909817-26-000003 · wk-form4_1770160963.xml · derivative · entry 3

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,096 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and vested as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and vested as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award.

SEC source: 0001909817-26-000003 · wk-form4_1770160963.xml · nonDerivative · entry 2

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,713

F2 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.

SEC source: 0001909817-26-000003 · wk-form4_1770160963.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,902

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes an aggregate of 241 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001643653-26-000008 · wk-form4_1770160887.xml · derivative · entry 3

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,294 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and vested as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award.

F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and vested as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award.

SEC source: 0001643653-26-000008 · wk-form4_1770160887.xml · nonDerivative · entry 2

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,755

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.

SEC source: 0001643653-26-000008 · wk-form4_1770160887.xml · nonDerivative · entry 1

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,047

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001724097-26-000003 · wk-form4_1770159979.xml · derivative · entry 3

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,437 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and vested as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and vested as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award.

SEC source: 0001724097-26-000003 · wk-form4_1770159979.xml · nonDerivative · entry 2

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,097

F2 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.

SEC source: 0001724097-26-000003 · wk-form4_1770159979.xml · nonDerivative · entry 1

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,465

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes an aggregate of 218 shares purchased on August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.